Company intelligence / Profile preview

Pluri Capital

Ownership: Private
Employees: ~140
Development stage: Commercial

Overview

Pluri develops placenta-derived allogeneic cell therapies using its proprietary scalable GMP-compliant “3D cell expansion” technology. Lead candidates include PLX-PAD for muscle injury and vascular diseases, and PLX-R18 for hematological recovery post-radiation or transplantation. Clinical results have shown safety and signals of efficacy in several indications including muscle regeneration after hip fracture surgery. The company also operates a CDMO division supporting external clients’ advanced therapies

Therapeutic areas: OtherPulmonologyCardiovascularHematology
Modalities: Cell therapyInduced pluripotent stem cell derived therapy (for some programs)Allogeneic cell therapyBiologic (general for cell-based products)
Industry: Biotech

Partnerships

Bar-Ilan University (cancer immunotherapy)various undisclosed CDMO clients

Beyond the preview

Go deeper on Pluri Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluri Capital.

Explore the full profile